What is the follicular center cell phenotype?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Follicular center phenotype refers to a specific classification of B-cell lymphomas that originate from or resemble the germinal center B-cells of lymph nodes, characterized by the expression of markers such as CD10, BCL-6, and often BCL-2, as noted in studies 1 and 1.

Key Characteristics

  • The follicular center phenotype is not equivalent to follicular lymphoma, as it can also occur in Burkitt lymphoma and some diffuse large B-cell lymphomas (DLBCL) 1.
  • Typical immunophenotype includes CD10+, BCL2+, CD23+/-, CD43-, CD5-, CD20+, cyclin D1-, BCL6+ 1.
  • Rare cases of follicular lymphoma may be CD10- or BCL2- 1.

Importance of Diagnosis

Understanding the follicular center phenotype is crucial for accurate diagnosis, as it helps distinguish these lymphomas from other B-cell malignancies and guides treatment decisions 1.

Biological Behavior

The phenotype reflects the cell of origin and provides insights into the biological behavior of these lymphomas, which typically follow an indolent clinical course in the case of follicular lymphoma 1.

Treatment Implications

Accurate diagnosis of the follicular center phenotype is essential for guiding treatment decisions, as different lymphomas with this phenotype may require distinct treatment approaches 1.

From the Research

Follicular Center Phenotype

  • The follicular center phenotype is associated with follicular lymphoma (FL), a type of non-Hodgkin's lymphoma that originates from the follicular center B cells 2.
  • Follicular center cell (FCC) lymphomas are characterized by the presence of surface immunoglobulin (Ig) and the absence of E rosette-forming cells, indicating their B-cell origin 2.
  • The follicular center phenotype is typically marked by the expression of specific surface antigens, such as CD19, CD20, and CD10, as well as the presence of monoclonal immunoglobulin 3.
  • The diagnosis of follicular lymphoma is based on histology from a biopsy of a lymph node or other affected tissue, and immunohistochemical staining is used to confirm the follicular center phenotype 3.

Immunologic Characteristics

  • Follicular center cell lymphomas are characterized by the presence of surface IgM, IgD, IgG, or IgA, and light-chain analysis shows a predominant light-chain type, indicating their monoclonal nature 2.
  • The neoplastic cells from follicular center cell lymphomas synthesize the surface Ig they bear, and the Ig-bearing cells have a polyclonal distribution in reactive tissues 2.
  • The follicular center phenotype is also associated with the expression of specific genes, such as the t(14;18) translocation involving the IgH/bcl-2 genes, which is present in the overwhelming majority of cases 3.

Clinical Significance

  • The follicular center phenotype is an important prognostic factor in follicular lymphoma, and the diagnosis and treatment of this disease are based on the characterization of the follicular center cells 3, 4, 5, 6.
  • The treatment of follicular lymphoma typically involves the use of rituximab, a monoclonal antibody that targets the CD20 antigen on the surface of B cells, including those with the follicular center phenotype 3, 4, 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Follicular lymphoma: 2023 update on diagnosis and management.

American journal of hematology, 2022

Research

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

European journal of haematology. Supplementum, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.